Omalizumab, an anti-immunoglobulin E antibody: State of the art

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 197-207

  Incorvaia, Cristoforo ^a   Mauro, Marina ^b   Russello, Marina ^b   Formigoni, Chiara ^b   Riario Sforza, Gian Galeazzo ^a   Ridolo, Erminia ^c  

^a PARKINSON INSTITUTE   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Anaphylaxis; Anti IgE; Asthma; Atopic dermatitis; Hypersensitivity; Immunoglobulin E; Mastocytosis; Omalizumab; Urticaria

Indexed keywords

ANTI-IGE ANTIBODIES; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; OMALIZUMAB;

ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASTHMA; FOOD HYPERSENSITIVITY; HUMAN; NASAL POLYPS; OFF LABEL DRUG USE; RHINITIS, ALLERGIC; SKIN DISEASES;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASTHMA; FOOD HYPERSENSITIVITY; HUMANS; NASAL POLYPS; OFF-LABEL USE; RHINITIS, ALLERGIC; SKIN DISEASES;

EID: 84893656522     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S49409     Document Type: Review

References (102)

1. Bennich HH, Ishizaka K, Johansson SG, Rowe DS, Stanworth DF, Terry WD. Immunoglobulin E: a new class of human immunoglobulin. Immunology. 1968;15:323-324.
2. Wide L, Bennich H, Johansson SG. Diagnosis of allergy by an in-vitro test for allergen antibodies. Lancet. 1967;2:1105-1107.
3. Siraganian RP. Mechanisms of IgE-mediated hypersensitivity. In: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, editors. Allergy. Principles and Practice. St Louis, MI: Mosby; 1993.
4. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
5. Jardieu PM, Fick RBJ. IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999;118:112-115.
6. Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med. 2001;164:S6-S11.
7. Milgrom H, Berger W, Najak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36.
8. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39: 788-797.
9. Hendeles L, Sorkness CA. Anti-immunoglobulin E therapy with omalizumab for asthma. Ann Pharmacother. 2007;41: 1397-1410.
10. De Bisschop MB, Bellou A. Anaphylaxis. Curr Opin Crit Care. 2012;18:308-317.
11. Simons A. Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital. Am J Respir Crit Care Med. 2010;181:A1336.
12. Worm M, Babina M, Hompes S. Causes and risk factors for anaphylaxis. J Dtsch Dermatol Ges. 2013;11:44-50.
13. Mauro M, Incorvaia C, Formigoni C, Elia R, Russello M, Pellegrino D. The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology. Panminerva Med. 2012;54:305-312.
14. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;2:CD003559.
15. D'Amato G, Perticone M, Bucchioni E, Salzillo A, D'Amato M, Liccardi G. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update. Eur Ann Allergy Clin Immunol. 2010;42:135-140.
16. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364:1005-1015.
17. Brusselle G, Michils A, Louis R, et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103:1633-1642.
18. Cazzola M, Camiciottoli G, Bonavia M, et al. Italian real-life experience of omalizumab. Respir Med. 2010;104:1410-1416.
19. Barnes N, Menzies-Gow A, Mansyr AH, et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real world study. J Asthma. 2013;50:529-536.
20. Grimaldi-Bensouda L, Zureik M, Aubier M, et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest. 2013;143:398-405.
21. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a one year real life survey. Eur Respir J. March 21, 2013. [Epub ahead of print.]
22. Garcia G, Magnan A, Chiron R, et al. A proof of concept randomized controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma. Chest. 2013;144:411-419.
23. Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy. 2009;39:1145-1151.
24. Marone G, Rossi FW, Detoraki A, et al. Role of superallergens in allergic disorders. Chem Immunol Allergy. 2007;93:195-213.
25. Luskova P, Draber P. Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors. Search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des. 2004;10: 1727-1737.
26. Zaidi AK, Saini SS, Macglashan DW. Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol. 2010;125:902-906.
27. Lavaud F, Bonniaud P, Dalphin JC, et al. Usefulness of omalizumab in the patients with severe occupational asthma. Allergy. 2013;68: 813-815.
28. Nopp A, Johansson SG, Adedoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy. 2010;65:56-60.
29. Incorvaia C, Masieri S, Scurati S, Soffia S, Puccinelli P, Frati F. The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children. J Asthma Allergy. 2011;4:13-17.
30. Bahadori K, Quon BS, Doyle-Waters MM, Marra C, Fitzgerald JM. A systematic review of economic evaluations of therapy in asthma. J Asthma Allergy. 2010;3:33-42.
31. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65:1141-1148.
32. Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis. 2012;6:87-95.
33. van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled asthma in The Netherlands. J Med Econ. 2013;16:342-348.
34. Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin e antibody, on airway wall thickening in asthma. Respiration. 2012;83:520-528.
35. Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infilitration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol. 2012;25:475-484.
36. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001;286:2956-2967.
37. Chervinsly P, Casale T, Townley R, et al. Omalizumab, and anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160-167.
38. Humbert M, Boulet LP, Niven RM, Panahloo Z, Blogg M, Ayre G. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy. 2009;64: 81-84.
39. Verbruggen K, Van Cauwenberge P, Bachert C. Anti-IgE for the treatment of allergic rhinitis-and eventually nasal polyps? Int Arch Allergy Immunol. 2009;148:87-98.
40. Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21:428-432.
41. Bains SN, Judson MA. Allergic bronchopulmonary aspergillosis. Clin Chest Med. 2012;33:265-281.
42. ven der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax. 2007;62:276-277.
43. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) with anti-IgE antibody (omalizumab). Pediatr Pulmonol. 2008;43:1249-1251.
44. Lebecque P, Leonard A, Argaz M, Godding V, Pilette C. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep. 2009;2009:pii: bcr07.2008.0379.
45. Lebecque P, Leonard A, Piletre C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol. 2009;44:516.
46. Collins J, Devos G, Hudes G, Rosenstreich D. Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy. 2012;5:65-70.
47. Wong R, Wong M, Robinson PD, Fitzgerald DA. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Paediatr Respir Rev. 2013;14:22-24.
48. Incorvaia C, Mauro M, Riario-Sforza GG, Frati F, Tarantini F, Caserini M. Current and future applications of the anti-IgE antibody omalizumab. Biologics. 2008;2:67-73.
49. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530-537.
50. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-randomized, placebo-controlled and double-blind pilot study. J Dtsch Dermatol Ges. 2010;8:990-998.
51. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol. 2006;117:1415-1418.
52. Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65: 931-932.
53. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy. 2010;65:138-139.
54. Güzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:1563-1565.
55. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63:247-249.
56. Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2010;125: 490-491.
57. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol. 2010;35:127-129.
58. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120:979-981.
59. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007;99:190-193.
60. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008;122:569-573.
61. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368: 924-935.
62. Siebenhaar F, Kühn W, Zuberbier T, Maurer M. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol. 2007;120:213-215.
63. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119: 1550-1551.
64. Rueff F, Dugas-Breit S, Przybilla B. Stinging Hymenoptera and mastocytosis. Curr Opin Allergy Clin Immunol. 2009;9:338-342.
65. Kontou-Fili K, Fili CI. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy. 2009;64:1384-1385.
66. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a non atopic patient. Allergy. 2010;65:926-927.
67. Bock SA, Munoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-193.
68. Leung DY, Sampson HA, Yunginger JW, et al. Effects of anti-IgE therapy in patients with peanut allergy. N Engl J Med. 2003;348:975-976.
69. Jones JD, Marney SR Jr, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol. 2008;101:550-551.
70. Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102:257-258.
71. Bray SM, Fajt ML, Petrov AA. Successful treatment of exercise-induced anaphylaxis with omalizumab. Ann Allergy Asthma Immunol. 2012;109: 281-282.
72. Robson-Ansley P, Toit GD. Pathophysiology, diagnosis and management of exercise-induced anaphylaxis. Curr Opin Allergy Clin Immunol. 2010;10:312-317.
73. Rafi ALT, Katz R, Sheinkopf LE, Simons CW, Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010;31:76-83.
74. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130:1123-1129.
75. Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol. 2007;120: 594-601.
76. Foster B, Foroughi S, Yin Y, Prussin C. Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders. Clin Mol Allergy. 2011;9:7.
77. Ridolo E, Montagni M, Olivieri E, Rogkakou A, De' Angelis GL, Canonica GW. Eosinophilic esophagitis: which role for food and inhalant allergens? Asia Pac Allergy. 2012;2:237-241.
78. Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr. 2011;170: 1471-1474.
79. Cabanes N, Igea JM, de la Hoz B, et al. Latex allergy: position paper. J Investig Allergol Clin Immunol. 2012;22:313-330.
80. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004;113:360-361.
81. Calonge M, Herreras JM. Clinical grading of atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7:442-445.
82. Williams PB, Sheppard JD Jr. Omalizumab: a future innovation for treatment of severe ocular allergy? Exp Opin Biol Ther. 2005;5: 1603-1609.
83. Taillé C, Doan S, Neukirch C, Aubier M. Omalizumab for severe atopic keratoconjunctivitis. BMJ Case Rep. 2010;2010:pii: bcr0420102919.
84. Bard S, Paravisini A, Avilés-Izquierdo JA, Fernandez-Cruz E, Sánchez-Ramón S. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol. 2008;144: 1662-1663.
85. Lee J, Doggweiler-Wiygul R, Kim S, Hill BD, Yoo TJ. Is interstitial cystitis an allergic disorder? A case of interstitial cystitis treated successfully with anti-IgE. Int J Urol. 2006;13:631-634.
86. Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123:704-705.
87. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48:318-324.
88. Bobolea I, Barranco P, Fiandor A, Cabañas R, Quirce S. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol. 2010;20:448-449.
89. Parks KW, Casale TB. Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc. 2006; 27 Suppl 1:S33-S36.
90. Incorvaia C, Frati F, Puccinelli P, Riario-Sforza GG, Dal Bo S. Dose dependence of efficacy and safety of subcutaneous immunotherapy. Monaldi Arch Chest Dis. 2006;65:41-43.
91. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383-389.
92. Kamin W, Kopp MV, Erdnuess F, Schauer U, Zielen S, Wahn U. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010;21:160-165.
93. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39:271-279.
94. Müller UR, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol. 1992;89:529-534.
95. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy. 2007;62:963-964.
96. Rerinck HC, Rueff F, Przybilla B. Recurrent severe anaphylactic reactions to venom immunotherapy (VIT): omalizumab induces tolerance. J Allergy Clin Immunol. 2008;Suppl 29:111.
97. Galera C, Soohun N, Zankar N, Caimmi S, Gallen C, Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009;19:225-229.
98. Soriano Gomis V, Gonzalez Delgado P, Niveiro Hernandez E. Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. J Investig Allergol Clin Immunol. 2008;18: 225-226.
99. Kopp MV. Omalizumab: and anti-IgE therapy in allergy. Curr Allergy Asthma Rep. 2011;11:101-116.
100. Sanchez J, Ramirez R, Diez S, et al. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012;40:306-315.
101. Babu KS, Polosa R, Morjaria JB. Anti-IgE-emerging opportunities for omalizumab. Expert Opin Biol Ther. 2013;13:765-777.
102. Shankar T, Petrov AA. Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2013;13:19-24.